Kancera AB (publ) Stock Nasdaq Stockholm
Equities
SE0015658570
Biotechnology & Medical Research
Sales 2023 | 1.03M 94.57K | Sales 2024 * | - | Capitalization | 175M 16.03M |
---|---|---|---|---|---|
Net income 2023 | -64M -5.85M | Net income 2024 * | -81M -7.4M | EV / Sales 2023 | 358 x |
Net cash position 2023 * | - 0 | Net cash position 2024 * | - 0 | EV / Sales 2024 * | - |
P/E ratio 2023 |
-9.28
x | P/E ratio 2024 * |
-2.07
x | Employees | - |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 37.38% |
Managers | Title | Age | Since |
---|---|---|---|
Peter Selin
CEO | Chief Executive Officer | - | 22-02-28 |
Director of Finance/CFO | 75 | - | |
Martin Norin
COO | Chief Operating Officer | 65 | 09-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 63 | 10-05-04 | |
Director/Board Member | 66 | 15-12-31 | |
Håkan Mellstedt
FOU | Founder | 82 | 10-04-27 |
1st Jan change | Capi. | |
---|---|---|
-1.96% | 103B | |
+0.46% | 95.71B | |
+1.69% | 22.02B | |
-16.71% | 20.9B | |
-9.30% | 17.85B | |
-41.01% | 16.21B | |
-15.02% | 15.52B | |
+3.86% | 13.86B | |
+35.10% | 12.04B |